IP Library Granted Patent US 10,179,118
Granted Patent B2
US 10,179,118 · App. 14/223,026 · Granted Jan 15, 2019

Pharmaceutical compositions of dimethyl fumarate

Inventors: Sami Karaborni (Cupertino, CA); Wei Chen (Cupertino, CA); Suresh Kumar Manthati (Sunnyvale, CA)
Assignee: ARBOR PHARMACEUTICALS, LLC
A61K31/336A61J1/035A61K31/194A61K31/215A61K31/225A61K31/343A61K31/381A61K31/403A61K9/4825
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,179,118
App. No.
14/223,026
Granted
Jan 15, 2019
Kind
B2
Abstract

Pharmaceutical compositions and dosage forms of dimethyl fumarate containing low levels of certain impurities are disclosed.

Claims (18)

1. A dosage form for treating multiple sclerosis, comprising:

(a) a therapeutically effective amount of dimethyl fumarate in solid form, wherein said dimethyl fumarate is the only drug in the dosage form; and

(b) one or more compounds of Formula (I):

isomers thereof and salts of any of the foregoing, wherein:

each of R 1 through R 4 is independently chosen from hydrogen and methyl wherein at least one of R 1 -R 4 is hydrogen; and wherein the one or more compounds of Formula (I) are impurities and are present in the dosage form in a combined total amount of 0.001% to 2% by weight based on total weight of the dimethyl fumarate; and

(c) a pharmaceutically acceptable vehicle.

2. The dosage form of claim 1 , wherein the one or more compounds of Formula (I) are present in a combined total amount of 0.001% to less than 1% by weight based on total weight of the dimethyl fumarate.

3. The dosage form of claim 1 , wherein the one or more compounds of Formula (I) are selected from 3,4-bis(methoxycarbonyl)cyclobutane-1,2-dicarboxylic acid, 2,4-bis(methoxycarbonyl)cyclobutane-1,3-dicarboxylic acid, cyclobutane-1,2,3,4-tetracarboxylic acid, and isomers thereof and salts of any of the foregoing.

4. The dosage form of claim 1 , wherein the one or more compounds of Formula I are 1R, 2R, 3S, 4S-isomers.

5. The dosage form of claim 3 , wherein each of the one or more compounds of Formula (I) is in an amount of 0.001% to 0.3% by weight based on total weight of the dimethyl fumarate.

6. The dosage form of claim 3 , wherein each of the one or more compounds of Formula (I) is in an amount of 0.001% to 0.2% by weight based on total weight of the dimethyl fumarate.

7. The dosage form of claim 1 , wherein the pharmaceutically acceptable vehicle is selected from a carrier, a diluent, an excipient, a wetting agent, an emulsifier, a buffer, a stabilizer, a thickener, a lubricant, a coloring agent and combinations thereof.

8. The dosage form of claim 1 , wherein the opaque coating is free of dimethyl fumarate.

9. The dosage form of claim 1 , wherein the dosage form is enclosed in a package that limits exposure of the dosage form to ambient light.

10. The dosage form of claim 9 , wherein the package is a bottle comprising an opaque polymer.

11. The dosage form of claim 9 , wherein the package is a blister pack comprising metal foil.

12. The dosage form of claim 11 , wherein the blister pack comprises an opaque polymer.

13. The dosage form of claim 1 wherein the dosage form is in the form of a tablet or capsule having an opaque coating comprising a compound selected from the group consisting of iron oxide, a colorant, titanium dioxide, zinc oxide and combinations thereof and the dosage form does not contain polyvinylpyrrolidine.

Assignments (8)
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Mar 17, 2025
From: ARBOR PHARMACEUTICALS, LLC; AZURITY PHARMACEUTICALS, INC.; AZURITY PHARMACEUTICALS IRELAND LIMITED; SILVERGATE PHARMACEUTICALS, INC.
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070531/0487 →
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: AZURITY PHARMACEUTICALS, INC.; SILVERGATE PHARMACEUTICALS, INC.; ARBOR PHARMACEUTICALS, LLC; SLAYBACK PHARMA LIMITED LIABILITY COMPANY
Reel/Frame 070521/0299 →
RELEASE OF SECURITY INTEREST Recorded Oct 20, 2021
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: ARBOR PHARMACEUTICALS, LLC; WILSHIRE PHARMACEUTICALS, INC.; XENOPORT, INC.
Reel/Frame 057880/0174 →
SECURITY INTEREST Recorded Sep 20, 2021
From: ARBOR PHARMACEUTICALS, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 057544/0803 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2018
From: XENOPORT, INC.
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 046633/0753 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2018
From: ARBOR PHARMACEUTICALS, LLC
To: XENOPORT, INC.
Reel/Frame 046449/0306 →
SECURITY INTEREST Recorded Jul 6, 2016
From: ARBOR PHARMACEUTICALS, LLC; XENOPORT, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 039266/0345 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2014
From: KARABORNI, SAMI; CHEN, WEI; MANTHATI, SURESH KUMAR
To: XENOPORT, INC.
Reel/Frame 032664/0220 →
Continuity (5)
Provisional Application 61805869 · Mar 27, 2013
Provisional Application 61805516 · Mar 26, 2013
Provisional Application 61805137 · Mar 25, 2013
Provisional Application 61804725 · Mar 24, 2013
Related Publication 20140284245A1 · Sep 25, 2014
Cited By (1)
US 12,440,468